Anthem Biosciences Limited (NSE:ANTHEM)
749.90
+2.25 (0.30%)
Jul 14, 2026, 3:30 PM IST
Anthem Biosciences Revenue
In the fiscal year ending March 31, 2026, Anthem Biosciences had annual revenue of 21.29B INR with 15.09% growth. Anthem Biosciences had revenue of 6.16B in the quarter ending March 31, 2026, with 26.01% growth.
Revenue
21.29B
Revenue Growth
+15.09%
P/S Ratio
19.84
Revenue / Employee
9.33M
Employees
2,282
Market Cap
422.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 21.29B | 2.79B | 15.09% |
| Mar 31, 2025 | 18.50B | 4.30B | 30.28% |
| Mar 31, 2024 | 14.20B | 3.62B | 34.24% |
| Mar 31, 2023 | 10.58B | -1.83B | -14.74% |
| Mar 31, 2022 | 12.41B | 1.35B | 12.24% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 169.27B |
| Dishman Carbogen Amcis | 29.32B |
| OneSource Specialty Pharma | 14.22B |
| Concord Biotech | 10.55B |
| Blue Jet Healthcare | 9.47B |
| Supriya Lifescience | 8.28B |
| Panacea Biotec | 6.40B |
| Zota Health Care | 5.39B |
Anthem Biosciences News
- 7 weeks ago - Anthem Biosciences Transcript: Q4 25/26 - Transcripts
- 7 weeks ago - Anthem Biosciences Quarterly report: Q4 2026 - Filings
- 7 weeks ago - Anthem Biosciences Slides: Q4 2026 - Filings
- 7 weeks ago - Anthem Biosciences Annual report: Q4 2026 - Filings
- 5 months ago - Anthem Biosciences Transcript: Q3 25/26 - Transcripts
- 5 months ago - Anthem Biosciences Quarterly report: Q3 2026 - Filings
- 5 months ago - Anthem Biosciences Slides: Q3 2026 - Filings
- 8 months ago - Anthem Biosciences Transcript: Q2 25/26 - Transcripts